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I have known Pat Brown for about two
decades and he never ceases to amaze me.
Over the years, I have heard him speak
quite a few times, and on each occasion I
can feel my jaw drop. What will he think
up next?
Pat (Image 1) is most frequently associ-
ated with the invention of microarrays and
their use in studying gene expression, and
he should be familiar to the readers of
PLoS as a driving force behind open-
access journals. But these are only two
examples of his many successes, which
span the worlds of topoisomerase, HIV
integration, protein microarrays, and post-
transcriptional regulation. Pat seems to
have a brain in overdrive and the energy
to match it. I was eager to tap into some of
that electricity during the interview.
I met Pat in his office on the fourth floor
of the Beckman building at Stanford, where
he is a member of the Biochemistry
Department. I arrived on a warm and
fragrant spring afternoon to find Pat bare-
foot, wrapping up a grant submission, and
obstructed by two large cardboard boxes of
assorted PLoS T-shirts. On his door was a
small poster: ‘‘Where would Jesus publish?’’
I knew Pat had an atypical family story,
so we started there. He is one of seven
talented siblings, who were encouraged by
their mother to think big and to make a
contribution. His father’s work led the
family to spend four years in Paris, where
Pat attended school in a quaint uniform of
shorts with white hat and socks, and a
second idyllic stint of four years in Taipei,
in a neighborhood surrounded by rice
paddies and water buffalo. In between, a
Washington, D. C. suburb was home. Pat
later discovered that his father did not
work for the State or Defense Depart-
ments, as he had been led to believe, but
rather the CIA, where he was an analyst.
We pick up the interview with discus-
sion of an extremely fertile period in the
early 1990s, when Pat was a new faculty
member at Stanford and about to launch
his work on DNA microarrays.
Gitschier: What was the initial think-
ing behind the microarray? I understand it
had more to do with facilitating genotyp-
ing than expression measurements.
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a scheme that had the ultimate aim of
determining whole-genome genotypes of
millions of people for linkage and associ-
ation studies. It involved a biochemical
method that we called ‘‘genomic mismatch
scanning’’ for isolating the sequences that
were identical between two genomes, and
then mapping them by hybridizing to a
physically ordered arrangement of the
human genome.
At the time, you could map a cloned
gene by FISH [fluorescence in situ hy-
bridization] to metaphase chromosomes
on slides, and that worked pretty well, but
it wasn’t scalable for the kind of experi-
ments I was planning to do. You couldn’t
have Uta Francke, for example, just doing
FISH after FISH experiment for all the
sequences that we would be generating
from this project.
I had a vision about how all this was
going to go. I had sent a little blurb to
Claire [Weinstock, an administrator at the
Howard Hughes Medical Institute] outlin-
ing my plan. I used red and green dots to
symbolize the microarrays, because I like
that color combination.
Gitschier: You obviously aren’t color
blind. FISH uses just a single fluorescent
probe, so why did you feel the need for a
two-color, comparative system for the
microarrays?
Brown: You need it to make reliable
measurements. Kallioniemi had developed
a method for complex probe comparative
hybridization to metaphase chromosomes
for looking at copy number variations.
And that was precisely the rationale. If you
were to just do a single probe hybridiza-
tion, you would have very inhomogeneous
patterns, only partially driven by the copy
number changes themselves, but also by
technical factors.
I had a small pilot grant from the
NHGRI [National Human Genome Re-
search Institute] to develop the genomic
mismatch scanning method, and once
Stan Nelson and I had that method
worked out, I submitted a renewal appli-
cation that included the microarrays.
I had a terrible experience with my
renewal. In retrospect, I felt it was one of
the best grant proposals I have written.
And it got the worst priority score of any
grant, not only of any grant I’ve ever
written, but any grant I’ve ever SEEN.
Gitschier: Because it was too ambi-
tious?
Brown: Yeah!
Gitschier: I can just imagine. They
probably said each one of these specific
aims is an entire grant.
Brown: The specific aims were 1. Take
what we’ve already been doing biochem-
ically [genomic mismatch hybridization]
and make it work better and focus on the
mammalian genomes instead of yeast. 2.
Develop the microarray system from
scratch. I said here’s how I think we can
do it, and it was pretty much exactly as we
did start to do it. Aim 3 was development
of statistical tools to take advantage of the
high-resolution genome-wide genotype.
Then I had an aim that we needed to
start to put together the infrastructure to
do this on a population basis. I had the
idea that West Virginia was going to be a
good place because it had the smallest
fraction of the population moving in and
out of the state. And there was yet another
aim I can’t remember.
I’m just trying to give you a sense of the
weirdness of the grant. This is at a stage
where all we had really done was to get
this biochemical thing working in yeast.
Gitschier: So this was 1992.
Brown: Yeah, we submitted it in
November 1992. And I thought, ‘‘This
grant just totally rocks.’’ And then I got the
little note-card back from the NIH [Na-
tional Institutes of Health]. I saw my
priority score: 344. I was just so totally
deflated that I literally had to lie down on
my office floor for ten minutes to regain
my composure.
I got back in touch with them [NHGRI]
and they said, ‘‘Just do aim 1 and resubmit
the grant.’’ I did resubmit, but even in the
grant proposal I said, ‘‘Following the
advice, I’m doing this, but I think it’s
BAD advice and when I do get the grant
I’m just going to be going ahead with
other things I had proposed.’’ It was kind
of stupid, but I was so pissed off that I just
didn’t want them to think that I was going
to knuckle under.
Gitschier: And did you get that grant?
Brown: Yeah. It was much smaller, but
I got it. Meanwhile I recruited Dari
[Shalon] to start the microarray work,
and that was a strange experience.
Gitschier: Tell me about it.
Brown: I went over to this building
called CIS [Center for Integrative Sys-
tems], which is where they have a whole
bunch of stuff set up, like the n-1
generation from micro-fabrication of the
chip industry. So I thought, ‘‘This is where
all the good stuff is for making very precise
tiny things and patterning them.’’ So I
went over there and just literally wandered
around, asking people who I should talk to
and I found Greg Kovacs, who was an
MD/PhD neurologist. He was interested
in building chips to be used for bionic
people, for sensing impulses in nerves and
controlling artificial limbs.
I got along well with him and told him
what I had in mind to do and how I
thought it could be done. I had it all laid
out, using robotic printing. He kept
wanting to make it a complicated elec-
tronic device. But I wanted it to be
incredibly simple, and I wanted to use
fluorescence read-out, not a circuit detect-
ing changes in capacitance, for example,
for a couple of reasons. One—I wanted to
be able to do two colors and have the
internal control, which you can’t do with
that direct sensing thing, and two—I
didn’t want some expensive high-tech
thing that was going to be finicky.
That wasn’t interesting to him, but he
said, ‘‘I have a very good rotation student
and this guy just wants to work on a
project that is practical.’’ What it came
down to was that he wanted something
that he could use to start a company.
So I thought, ‘‘Fine, that’s easy!’’ So I
met with the guy [Dari] and told him the
main thing I thought it would be good for
commercially, which turned out not to be
true, was for medical diagnostics. That
you could build an array that would
monitor the expression patterns in white
blood cells. That these cells were acting
like spies, that they were circulating to
every part of the body—their whole
purpose in life was to detect any kind of
trouble and orchestrate a response, which
involves a transcriptional program. So
therefore, you should be able to take a
drop of blood and look at what genes are
expressed in white blood cells and figure
out what they are seeing as an all purpose
diagnostic.
Anyway, this is just an example of my
attempts to lure him into the project. My
pitch wasn’t correct, but it had the effect of
getting him to work on it. So Dari signs
on. And I also had to give him clearance
that if he developed something he could
then take it and turn it into a commercial
product.
Gitschier: Did he physically do this
work in your lab?
Brown: Yes, but you had to live with
Dari’s personality. He was not an adorable
guy.
Before Dari came in, I had this whole
thing mapped out, an XY robot, we’d
have stuff in micro-well plates and just
dot spots. I wanted to use a system like a
fountain pen because it’s simple and
robust—500-year-old technology. Dari
wasn’t too keen on that. He had a lot
of ideas of his own; for example, he
wanted to print on a linear tape which
you’d scan by pulling it through some
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all, but he thought it might be a better
system for scanning. There were a whole
bunch of ideas, but finally we returned to
the capillary printing thing. And that
worked fine.
Gitschier: Had capillary printing been
done before?
Brown: Not that I know of, but it must
have been. The idea is so fundamental.
Gitschier: But you had this idea of a
little fountain pen picking up a little bit of
liquid, depositing it, going back and
picking up something else.
Brown: Yes, the first model I had was
from doing electron microscopy. When
you pick up a grid, you hold it with these
very fine tweezers and you put a little drop
of stain on, and this annoying thing
happens, not infrequently, that the little
drop gets wicked up in the tweezers. And I
had been doing some electron microscopy
of some virus stuff. So literally the first
things we used to do printing were tips of
electron microscopy tweezers held togeth-
er with a little epoxy to serve as our pen.
So it was turning this annoying property of
electron microscopy tweezers into some-
thing useful.
Gitschier: So where did you get the
robotics? Did you build it?
Brown: Dari built the first one. Mean-
while, Joe [DeRisi] came to my lab to
work on retrovirology stuff. I was trying to
get him involved in the microarray stuff
because I was trying to shift the center of
gravity of the lab, but initially he wasn’t
buying it. But then, he was in the bay just
down from Dari and eventually he got so
annoyed that he felt he had to step in and
do it better. Joe built the second and third
generation printers. His robots are much
better and fancier.
Gitschier: Eventually, though, Dari
got something gridded.
Brown: Probably in less than a year. I
have Dari’s thesis somewhere up here.
[Shows me.] Here is fluorescent DNA
arrayed on the slide, just to show you can
do it.
Gitschier: OK, so now we know we
have DNA on slides, and we’re going to do
an experiment. The first one that is
published is the Schena paper, which is
an expression experiment and Arabidopsis
at that. It has nothing to do with your
original intent of genotyping. Tell me
about that turn of events.
Brown: We [Stanford Biochemistry
Department] have these yearly retreats.
Dari was up to present from my group,
and it might have been even in the same
session as Mark Schena, who was in Ron
Davis’s lab. Mark talked about an exper-
iment that he was trying to do. And this
was the first talk about the Affy [Affyme-
trix] array.
Gitschier: So, just a sec. Somewhere
in here, Affy is a player?
Brown: They had published a paper
on putting optically encoded peptides on
chips, a fantastic paper. Then we heard
that they were working on doing this with
oligonucleotides. And I knew they were at
very early stages, able to make only 8-
mers. Mark was trying to see if you could
use those arrays to look at mRNA
expression. But it didn’t work at all—you
got completely non-specific hybridization.
So immediately after he talked, and
Dari had just given his talk, those two guys
launched a collaboration, since we had
microarrays that were clearly working. We
had printed arrays with a bunch of
different DNA sequences and different
probes. Very high signal to noise.
Mark’s idea was to take an isogenic
strain overexpressing some transcription
factor [and to look at the differences in
expression profile compared to control],
and I wanted to look at different parts of
the plant, but it was all about a cute
proof-of-principle experiment more than
biology. It was a simple experiment
because he had a bunch of cDNA clones
and RNA isolated, just a matter of
labeling it. Within a month or two, we
had data for a paper.
The next interesting paper, as far as I
was concerned, was the paper in which Joe
was the first author. It was one of my all-
time favorite papers. It was what we were
going for from the get-go which is to be
able to look at a whole genome.
Gitschier: But this thing with Schena
and the expression tipped what kind of
questions you were going to ask.
Brown: Right. One thing about the
Arabidopsis experiment that made a big
impression on me was that even by looking
at a trivial number of genes, suddenly you
could see a picture that is telling you the
difference between a leaf and a root.
I just got very excited about it. You
don’t have to know anything about the
mechanism at all. It made me switch gears
and made me realize that actually, if you
say that genetics is relating variation in the
genome to variation in phenotype, there is
more accessible variation in expression
than there is in sequence, and there is
more variation in phenotype between cells
and tissues and organs than there is
between people. From the standpoint of
figuring out biology, that was probably the
angle that was going to be more powerful.
What really tipped the balance was Joe’s
experiment on the diauxic shift, where a
whole bunch of things became clear to me
for the first time. How powerful it was to
look for sets of genes that had correlated
expression and how much information
that carried about phenotype. Also, the
fact that you could take a genome, in
which only a third of the genes are
annotated, and by looking at their patterns
of expression, make pretty strong guesses
about what they [the unannotated genes]
may be doing. At that point, I thought, I
still love genetics, but this is SO the low-
hanging fruit! From the standpoint of
doing exploratory experiments and dis-
covering things—it was going to be way
more fun.
People in the lab who were doing
experiments just looking at gene expres-
sion patterns were just turning the crank.
For them it was—have an interesting idea
for a biological experiment, get data.
Genotyping just couldn’t compete any
more.
Gitschier: I couldn’t help but wonder,
though, whether at some point the tail
started wagging the dog. In other words,
have you found yourself in a situation
where you were too successful so that your
time has been spent, maybe in these bigger
collaborations…
Brown: You are so dead on!
Gitschier: …possibly to the detriment
of your own creativity.
Brown: I feel that there is a lot of truth
in that because I can get excited about just
about anything! In the early days, I
thought the best possible thing to do—
and I told people in my lab to just roll with
me on this one—was to seize any oppor-
tunity to get other people to provide us
with the best possible samples. Because I
thought that a large part of the way we
were going to be able to make sense of
every experiment we did was to collect a
huge body of data. Data would have
emergent properties that would make
every little bit of it make sense. You could
learn the dictionary of how to make sense
of how the genome’s language was used.
So, I was very promiscuous in terms of
soliciting and when solicited, saying yes to
collaborations. But what happened was
that, very early on, I realized that we had
not looked ahead enough. We had tons of
things that could turn into papers, but a
limited capacity to stop and write papers,
especially when a collaborator would take
some morsel that was very interesting and
want to write a paper on it, but for me it
was just one piece of the puzzle. We had
experience in turning the data into a story,
so we couldn’t just hand off the data to
people [without our help]. So that became
a big drain.
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was all very worthwhile. But there is a
point at which you sort of know what the
answer is going to look like, and where it is
headed, and it’s very important to see it
through, but at that point for me, I’m
ready to hand this off.
Gitschier: OK. May I ask about this
grant application? I see some tissue
staining [on the computer screen].
Brown: It’s about developing meth-
odology and software so that you could
use a variety of different antibody stains
and chemical stains in tissues, and for
each one you have a quantitative value,
for each pixel you have a vector of
values, and you can cluster them the way
you do for microarray data, to find
things that are similar. And then you
color code the images. And in this way,
you can actually see specific cell types
and pick up subtle quantitative differenc-
es in the staining.
One of the things I’m most interested in
is that in most tissues, there is a lot more
personality to the cells than you think. So I
wanted to develop a way to look at a tissue
section and say, these aren’t just fibroblasts
here, but actually 30 different kinds of
cells.
This is going to be a really great
diagnostic tool too. I want it to be really
cheap and fast. You can stain a tissue with
a few stains and the code takes almost no
time to run. I showed this to Mark
Krasnow and he said ‘‘We’ve been trying
like hell to find a stain that showed a
difference between these two cells,’’ and
here we just threw on a few stains with
absolutely no specificity for them, but the
pixel clustering pulled out subtle quantita-
tive differences in the staining and cleanly
separated them. It’s just like in FACS
sorting [fluorescence-activated cell sort-
ing].
Gitschier: This is very cool!
Brown: Ask me about my next big
project.
Gitschier: OK, but first let’s spend a
minute on the genesis of PLoS.
Brown: I want to LITERALLY over-
throw the scientific publishing establish-
ment.
Gitschier: Do you want to say that
again, only louder?
Brown: That is what I want to do.
PLoS is just part of a longer range plan.
The idea is to completely change the way
the whole system works for scientific
communication.
At the start, I knew nothing about the
scientific publishing business. I just decid-
ed this would be a fun and important thing
to do. Mike Eisen, who was a post-doc in
my lab, and I have been brain-storming a
strategic plan, and PLoS was a large part
of it. When I started working on this,
almost everyone said, ‘‘You are completely
out of your mind. You are obviously a
complete idiot about how publishing
works, and besides, this is a dilettante
thing that you’re doing.’’ Which I didn’t
feel at all.
I know I’m serious about it and I know
it’s doable and I know it’s going to be easy.
I could see the thermodynamics were in
my favor, because the system is not in its
lowest energy state. It’s going to be much
more economically efficient and serve the
customers a lot better being open access.
You just need a catalyst to GET it there.
And part of the strategy to get it over the
energy barrier is to apply heat—literally, I
piss people off all the time.
Gitschier: OK, Pat, with that, I think
I’m ready to hear about the NEXT big
project.
Brown: OK—I’m serious, and I’m
going to do my sabbatical on this: I am
going to devote myself, for a year, to trying
to the maximum extent possible to elim-
inate animal farming on the planet Earth.
Gitschier: [Pause. Sensation of jaw
dropping.]
Brown: And you are thinking I’m out
of my mind.
Gitschier: [Continued silence.]
Brown: I feel like I can go a long way
toward doing it, and I love the project
because it is purely strategy. And it
involves learning about economics, agri-
culture, world trade, behavioral psycholo-
gy, and even an interesting component of
it is creative food science.
Animal farming is by far the most
environmentally destructive identified
practice on the planet. Do you believe
that? More greenhouse production than
all transportation combined. It is also the
major single source of water pollution on
the planet. It is incredibly destructive. The
major reason reefs are dying off and dead
zones exist in the ocean—from nutrient
run-off. Overwhelmingly it is the largest
driving force of deforestation. And the
leading cause of biodiversity loss.
And if you think I’m bullshitting, the
Food and Agricultural Organization of the
UN, whose job is to promote agricultural
development, published a study, not
knowing what they were getting into,
looking at the environmental impact of
animal farming, and it is a beautiful study!
And the bottom line is that it is the most
destructive and fastest growing environ-
mental problem.
Gitschier: So what is your plan?
Brown: The gist of my strategy is to
rigorously calculate the costs of repairing
and mitigating all the environmental
damage and make the case that if we
don’t pay as we go for this, we are just
dumping this huge burden on our chil-
dren. Paying these costs will drive up the
price of a Big Mac and consumption will
go down a lot. The other thing is to come
up with yummy, nutritious, affordable
mass-marketable alternatives, so that peo-
ple who are totally addicted to animal
foods will find alternatives that are inher-
ently attractive to eat, so much so that
McDonald’s will market them, too. I want
to recruit the world’s most creative chefs—
here’s a REAL creative challenge!
I’ve talked with a lot of smart people
who are very keen on it actually. They say,
‘‘You have no chance of success, but I
really hope you’re successful.’’ That’s just
the kind of project I love.
Do you feel like you are ridiculously
optimistic?
Gitschier: Me? Yeah, sometimes. I
have my share of wild ideas. But you—you
want a revolution.
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